Kristie Blum

基本信息

Career Trajectory

Bio

Dr. Blum is co-chair of the NCI Lymphoma Steering Committee. She is also a member of the Lymphoma Research Foundation Scientific Advisory Board, the Alliance Co-Operative Group Lymphoma Committee, the American Society of Hematology Clinical Research Mentoring Program, and the National Comprehensive Cancer Network Hodgkin's Lymphoma Panel. She developed and chaired the first two Lymphoma Research Foundation Clinical Research Mentoring Programs from 2013-2015.

Research Interests

Papers共 43 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma

The New England journal of medicineno. 15 (2024): 1379-1389

Cited9Views0WOSBibtex

Combination of the PD‐1 Inhibitor Nivolumab and Immunomodulatory Drug Lenalidomide in Relapsed Hodgkin and Large B‐cell Lymphoma: Results from a Phase I/II Study

Hematological Oncologyno. S2 (2023): 597-598

Cited2Views0Bibtex

Efficacy of Brentuximab Consolidation by Metabolic Response in an International Real‐world Cohort of Classic Hodgkin Lymphoma at High Risk for Progression after ASCT

S. H. Desai,A. Smith,M. Spinner,A. Sykorova,V. Bachanova,A. M. Evens,G. Goyal,B. Kahl,K. Dorritie,J. Azzi,V. P. Kenkre,C. Chang,J. Michalka, B. Fusco,N. Sumransub,H. Hatic, R. Saba,U. Ibrahim,E. I. Harris,H. Shah,N. Wagner‐Johnston,S. Arai, H. Mockikova,D. Jagadeesh,K. A. Blum,C. Diefenbach,S. Geyer,S. Iyenger, K. Rapazzo,F. Baidoun,Y. Choi,R. H. Advani,V. Prochazka,I. Micallef

Hematological Oncologyno. S2 (2023): 361-362

Cited1Views0Bibtex

A Phase 1 Trial of Ibrutinib Plus Palbociclib in Previously Treated Mantle Cell Lymphoma (vol 133, Pg 1201, 2019)

P. Martin,N. L. Bartlett,K. A. Blum

BLOOD（2019）

Cited57Views0Bibtex

A Phase I Study of CPI-0610, a Bromodomain and Extra Terminal Protein (BET) Inhibitor in Patients with Relapsed or Refractory Lymphoma

K. A. Blum,J. Abramson,M. Maris,I. Flinn,A. Goy,J. Mertz,R. Sims, F. Garner,A. Senderowicz,A. Younes

Annals of Oncology（2018）

Cited46Views0Bibtex

Clinical Use of Pi3k Inhibitors in B-Cell Lymphoid Malignancies: Today and Tomorrow

I. B. Greenwell,C. R. Flowers,K. A. Blum,J. B. Cohen

EXPERT REVIEW OF ANTICANCER THERAPY（2017）

Cited50Views0WOSBibtex

A Phase II Trial of Lenalidomide Plus Rituximab in Previously Untreated Follicular Non-Hodgkin’s Lymphoma (NHL): CALGB 50803 (Alliance)

P. Martin,S-H Jung,B. Pitcher,N. L. Bartlett,K. A. Blum,T. Shea,E. D. Hsi,J. Ruan,S. E. Smith,J. P. Leonard,B. D. Cheson

Annals of Oncology（2017）

Cited82Views0WOSBibtex

BEYOND MAXIMUM GRADE: A NOVEL, LONGITUDINAL TOXICITY OVER TIME (TOXT) ADVERSE EVENT ANALYSIS OF LENALIDOMIDE IN FOLLICULAR LYMPHOMA IN CALGB 50401 (ALLIANCE)

G. Thanarajasingam,A.C. Dueck,P.J. Novotny,T.E. Witzig,T.M. Habermann,G.S. Nowakowski,C.R. Flowers,N.L. Bartlett,K.A. Blum,B.N. Pitcher,S. Jung,P.J. Atherton,A.D. Tan,J.A. Sloan,J.P. Leonard

Hematological Oncologyno. S2 (2017): 213-215

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn

Professor

Papers共 43 篇Author StatisticsCo-AuthorSimilar Experts